白介素-11治疗肝硬化所致血小板减少症

Clinical Study of rhIL-11 for the Management of Thrombocytopenia due to Hepatocirrhosis

目的观察白介素11(rhIL11)治疗肝硬化血小板减少的疗效与毒性。方法对照组24例肝硬化血小板减少病人,常规给予止血、氨肽素治疗;治疗组18例应用白介素11皮下注射治疗,平均用药10d。观察血小板升高情况及副作用。结果对照组血小板均无明显升高;治疗组白介素11应用5d内血小板开始升高,平均20d达最高峰;主要副作用为浮肿、乏力、头痛头晕、肌肉关节疼痛。结论白介素11能有效治疗肝硬化所致的血小板减少,血小板计数回升相对缓慢,作用持续时间较长,耐受性好。

Objective：To observe the effectiveness and safety profile of recombinant human interlukin-11 （rhIL-11） in the treatment of-thrombocytopenia due to hepatocirrhosis. Methods：Forty two patients were divided two groups, the treatment group and the control group. Tweenty-four patients of the control group received regular treatment project including hemostasis and ampeptide elemente. Eighteen patients of the treatment group received rhIL-11 at the dose of 1.5 mg subcutaneously for 10 days. Their serial changes in blood platelet count and side effects were recorded and compared with before. Results：No obvious change was observed in the platelet counts of the control group. For the treatment group,the median time required for a platelet recovery was 5 days and the maximum platelet count appeared at day 15 after rhlL-11 administration. Major adverse reaction included edema, headache, and pain of muscle and joint. Conclusion.rhIL-11 is an effective and safe agent for the management of hepatocirrhosis-secondary thrombocytopenia, with a relativel slow but sustained recovery of platelet count.